BLA 103772 · Centocor INC
Remicade
Infliximab · Tumor Necrosis Factor Blocker
NovelAccelerated approvalPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Feb 28, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1998
Aug 24, 1998
Approved uses
17
Original approval plus efficacy supplements
Registered trials
379
125 Phase 3, 45 recruiting
FAERS reports
217,587
192,742 serious, 14,068 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SERIOUS INFECTIONS and MALIGNANCY WARNING: SERIOUS INFECTIONS and MALIGNANCY See full prescribing information for complete boxed warning. Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis) and infections due to other opportunistic pathogens. ( 5.1 ) Discontinue Infliximab if a patient develops a serious infection. Perform test for latent TB; if positive, start treatment for TB prior to starting Infliximab. Monitor all patients for active TB during treatment, even if initial latent TB test is negative. ( 5.1 ) Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with tumor necrosis factor (TNF) blockers, including Infliximab. ( 5.2 ) Postmarketing cases of fatal hepatosplenic T-cell lymphoma (HSTCL) have...
What it is approved for
From the label in effect Feb 11, 2026.
Infliximab is a tumor necrosis factor (TNF) blocker indicated for: Crohn's Disease : reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.1 ) reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing disease. ( 1.1 ) Pediatric Crohn's Disease : reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.2 ) Ulcerative Colitis : reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.3 ) Pediatric Ulcerative Colitis : reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.4 ) Rheumatoid Arthritis in combination with methotrexate : reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active disease. ( 1.5 ) Ankylosing Spondylitis : reducing signs and symptoms in adult patients with active disease. ( 1.6 ) Psoriatic Arthritis : reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients. ( 1.7 ) Plaque Psoriasis :...
Mechanism: Infliximab neutralizes the biological activity of TNFα by binding with high affinity to the soluble and transmembrane forms of TNFα and inhibits binding of TNFα with its receptors. Infliximab does not neutralize TNFβ (lymphotoxin-α), a related cytokine that utilizes the same receptors as TNFα. Biological activities attributed to TNFα include: induction of pro-inflammatory cytokines such as interleukins (IL) 1 and 6, enhancement of leukocyte migration by increasing endothelial layer permeability and expression of adhesion molecules by endothelial cells and leukocytes, activation of neutrophil...
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 23, 2011 Supplement 5301 · Efficacy · priority review OrphanLabelLetter
- Apr 19, 2007 Supplement 5160 · Efficacy OrphanLabelLetter
- Oct 13, 2006 Supplement 5145 · Efficacy LetterLabel
- Sep 26, 2006 Supplement 5129 · Efficacy LabelLetter
- Aug 11, 2006 Supplement 5166 · Efficacy LetterLabel
- Aug 11, 2006 Supplement 5167 · Efficacy LabelLetter
- May 19, 2006 Supplement 5138 · Efficacy · priority review OrphanLabelLetter
- Sep 15, 2005 Supplement 5113 · Efficacy · priority review LetterLabelReview
- May 13, 2005 Supplement 5089 · Efficacy LabelLetter
- Dec 17, 2004 Supplement 5077 · Efficacy LabelLetter
- Sep 29, 2004 Supplement 5073 · Efficacy LabelPatient Package InsertLetter
- Apr 1, 2003 Supplement 5032 · Efficacy · priority review OrphanLetter
- Jun 28, 2002 Supplement 5012 · Efficacy · priority review LabelLetter
- Feb 27, 2002 Supplement 5004 · Efficacy LabelLetter
- Dec 29, 2000 Supplement 1007 · Efficacy · priority review LetterLabelReview
- Nov 10, 1999 Supplement 1004 · Efficacy ReviewLabelLetter
- Aug 24, 1998 Original approval · Type 1 - New Molecular Entity · priority review LabelReviewOther Important Information from FDA
1 products under this application
- REMICADE · INFLIXIMAB 100MG · VIAL, · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Infliximab" as an intervention, any sponsor and status, largest first.
- Treatments for COVID-19: Canadian Arm of the SOLIDARITY TrialPivotal-lookingStatus unknown
Sunnybrook Health Sciences CentreAcademic, hospital or other
NCT04330690 · 2,900 participants (planned) · Start Mar 18, 2020 · Primary completion Mar 10, 2024
Drug: Artesunate; Imatinib and 3 more · For: COVID-19
Sites: Calgary, Canada; Edmonton, Canada; Kamloops, Canada · 53 sites in all
- Immune Modulators for Treating COVID-19Pivotal-lookingCompleted
Daniel BenjaminAcademic, hospital or other
NCT04593940 · 1,971 participants · Start Oct 15, 2020 · Primary completion Jan 30, 2022
Drug: Infliximab; Abatacept and 2 more · For: Covid19
Sites: Phoenix, Arizona; Little Rock, Arkansas; La Jolla, California · 91 sites in all
- Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF TherapyPivotal-lookingCompleted
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT00124982 · 1,286 participants · Start Apr 2005 · Primary completion Aug 2009
Drug: Abatacept; Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD) and 1 more · For: Rheumatoid Arthritis
Sites: Birmingham, Alabama; Huntsville, Alabama; Paradise Valley, Arizona · 148 sites in all
- Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's DiseaseActive, not recruiting
Connecticut Children's Medical CenterAcademic, hospital or other
NCT05781152 · 1,270 participants · Start Jun 10, 2023 · Primary completion Jul 1, 2028
Drug: Anti-TNF therapy · For: Crohn Disease
Sites: Phoenix, Arizona; Los Angeles, California; San Diego, California · 26 sites in all
- Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological ImmunotherapieRecruiting
IsalaAcademic, hospital or other
NCT06031233 · 1,082 participants (planned) · Start Sep 1, 2023 · Primary completion Jul 2028
Drug: Nivolumab; Pembrolizumab and 9 more · For: Oncology; Infusion Reaction
Sites: Zwolle, Netherlands
- Treatment of the Human Anti-TNF Monoclonal Antibody Adalimumab in Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab (CHOICE)Pivotal-lookingCompleted
AbbottIndustry
NCT00338650 · 1,000 participants · Start Jun 2006
Drug: adalimumab · For: Crohn's Disease
Sites: Birmingham, Alabama; Jonesboro, Arkansas; Little Rock, Arkansas · 97 sites in all
- HLADQA1*05 Genotype and the Efficacy of Treatment With Infliximab in Chinese Population Crohn's DiseasePivotal-lookingStatus unknown
Sixth Affiliated Hospital, Sun Yat-sen UniversityAcademic, hospital or other
NCT05813860 · 976 participants (planned) · Start Apr 30, 2023 · Primary completion May 31, 2026
Drug: Azathioprine; Infliximab · For: Crohn Disease; Infliximab
- The Effects of Infliximab Versus Methotrexate in the Treatment of Moderate to Severe Psoriasis (Study P04271AM2)(COMPLETED)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT00251641 · 868 participants · Start Sep 1, 2005 · Primary completion Jun 1, 2008
Drug: infliximab; methotrexate · For: Psoriasis
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective39,857
- off label use39,149
- condition aggravated20,002
- infusion related reaction19,191
- pain18,649
- rheumatoid arthritis18,613
- arthralgia17,843
- fatigue16,776
- rash13,431
- product use issue13,143
- intentional product use issue13,103
- drug intolerance12,543
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 3,914 |
| 2005 | 3,404 |
| 2006 | 3,607 |
| 2007 | 4,090 |
| 2008 | 4,335 |
| 2009 | 5,091 |
| 2010 | 6,225 |
| 2011 | 8,099 |
| 2012 | 12,244 |
| 2013 | 9,120 |
| 2014 | 5,999 |
| 2015 | 12,316 |
| 2016 | 9,599 |
| 2017 | 10,037 |
| 2018 | 11,094 |
| 2019 | 13,337 |
| 2020 | 17,812 |
| 2021 | 13,063 |
| 2022 | 18,658 |
| 2023 | 14,184 |
| 2024 | 12,379 |
| 2025 | 12,090 |
| 2026 | 6,872 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Remicade (Infliximab)
2024 spending
$119M
Beneficiaries
3,243
17,640 claims
Per beneficiary
$36,632
$1,068.59 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $99,404,194 |
| 2021 | $102,739,191 |
| 2022 | $102,555,823 |
| 2023 | $111,268,849 |
| 2024 | $118,798,517 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative efficacy of biologics and oral agents in palmoplantar psoriasis and palmoplantar pustulosis: A systematic review and network meta-analysis of randomized clinical trials.
Spencer RK, Jin JQ, Elhage KG, et al. · J Am Acad Dermatol 2023 · Letter, Network Meta-Analysis
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.
Hanauer SB, Feagan BG, Lichtenstein GR, et al. · Lancet 2002 · Clinical Trial, Multicenter Study
- Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis.
Singh S, Murad MH, Fumery M, et al. · Lancet Gastroenterol Hepatol 2021 · Comparative Study, Research Support, N.I.H., Extramural
- Infliximab versus Cyclophosphamide for Severe Behçet's Syndrome.
Saadoun D, Maalouf G, Vieira M, et al. · NEJM Evid 2024 · Clinical Trial, Phase II, Comparative Study
- Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn's disease: systematic review and network meta-analysis.
Barberio B, Gracie DJ, Black CJ, et al. · Gut 2023 · Systematic Review, Network Meta-Analysis
- Infliximab for induction and maintenance therapy for ulcerative colitis.
Rutgeerts P, Sandborn WJ, Feagan BG, et al. · N Engl J Med 2005 · Multicenter Study, Randomized Controlled Trial
Sponsor: Johnson & Johnson (Janssen)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.